CSI Market
Sign In | Register

Day One Biopharmaceuticals Inc (DAWN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access DAWN Annual Cash Flow →
The data below summarizes Day One Biopharmaceuticals Inc's cash flow activity from Dec 31 2024 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Sep 30 2025) (Jun 30 2025) (Mar 31 2025) (Dec 31 2024)
Operating Activities
Income-107.32
Depreciation & amortization0.37
Amortization of Other Assets3.11
Increase (Decrease) in Deferred Revenue0.25
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories and Other Operating Assets-2.86
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.07
Share-based Compensation44.39
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Operating Lease Right Of Use Asset Amortization Expense0.20
Increase Decrease In Accrued Expenses And Other Current Liabilities-22.42
Acquired In Process Research And Development Asset-
Increase Decrease In Operating Lease Liability0.07
Income taxes0.00
Gain on Sale of Investments0.00
Increase (Decrease) in Accounts Receivable-12.86
Increase (Decrease) in Accounts Payable0.47
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets2.37
Other Working Capital-0.28
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-15.74
Discontinued operations0.00
Net Cash flow from Operating Activities-103.76
Investing Activities
Capital Expenditures-3.82
Sale of Capital Items0.03
Short-term Investments Proceeds-685.84
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Process Research And Development Assets-
Proceeds From Maturity Of Short Term Investments648.82
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale and Maturity of Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Proceeds from Sale of Other Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities174.65
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.22
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock Upon Employee Stock Purchase Plan Purchase-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.22
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-107.55
Total Cash Flow72.11
4 historic quarters locked

Sign in to unlock the full Day One Biopharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Day One Biopharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-25-264649

Figures are derived from filed reports and may be restated. Historical data is subject to revision.